A Phase 3 interventional study of Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) and Naproxen Sodium 440 mg (BAYH6689) in Pain, Postoperative, sponsored by Bayer. Completed at 2 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-08.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.
Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 4th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.
Browse Pain, Postoperative studies →2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 2008; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 75 across 4,854 interventional studies indexed under Pain, Postoperative.
Median enrollment 200 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 7 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 5 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing naproxen in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
Drug: Naproxen Sodium 440 mg (BAYH6689)
Drug: DPH 50 mg
Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Wake Time After Sleep Onset (WASO) Measured by Actigraphy
WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Sleep Latency Measured by Actigraphy
Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Total Sleep Time Measured by Actigraphy
Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Sleep Efficiency Measured by Actigraphy
Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Global Assessment of Investigational Product as a Sleep Aid
The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).
Time frame: Up to 10 hours
Karolinska Sleep Diary - Sleep Quality
Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Calmness of Sleep
Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Easiness to Fall Asleep
Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Premature Awakening
Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Ease of Awakening
Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Well Rested
Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)
Time frame: Up to 10 hours
Karolinska Sleep Diary - Sufficient Sleep
Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)
Time frame: Up to 10 hours
Subjective Sleep Questionnaire - Quality of Your Sleep Last Night
Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.
Time frame: Up to 10 hours
Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night
Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)
Time frame: Up to 10 hours
Subjective Sleep Questionnaire - Time to Fall Asleep Last Night
Subjects responded to Estimate of how long it took to fall asleep (minutes)
Time frame: Up to 10 hours
Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed
Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)
Time frame: Up to 10 hours
Change From Baseline in Pain Intensity
Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain
Time frame: Baseline and up to 10 hours
Overall Rating of Pain Relief
The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).
Time frame: Up to 10 hours
Time to Rescue Medication
If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded
Time frame: Up to 10 hours
Cumulative Proportion of Participants Taking Rescue Medication by Hour
If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded
Time frame: Up to 10 hours
Global Assessment of Investigational Product as a Pain Reliever
The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).
Time frame: Up to 10 hours
Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2
Time frame: Baseline and day 2
Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2
Time frame: Baseline and Day 2
Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2
Time frame: Baseline and day 2
Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2
Time frame: Baseline and day 2
| Milestone | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Started | 107 | 106 | 54 |
| Completed | 107 | 106 | 54 |
| Not completed | 0 | 0 | 0 |
WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Wake Time After Sleep Onset (WASO) Measured by Actigraphy | 155.25 (121.57 to 188.93) | 180.08 (146.36 to 213.80) | 364.83 (317.52 to 412.15) |
Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Sleep Latency Measured by Actigraphy | 23.50 (18.00 to 28.00) | 16.75 (13.50 to 25.00) | 27.50 (16.00 to 36.50) |
Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Total Sleep Time Measured by Actigraphy | 418.66 (385.05 to 452.28) | 392.38 (358.72 to 426.03) | 206.61 (159.39 to 253.84) |
Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Percent of sleep time during in-bed time | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Sleep Efficiency Measured by Actigraphy | 69.777 (64.175 to 75.380) | 65.396 (59.787 to 71.006) | 34.436 (26.566 to 42.306) |
The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 0 = Poor | 2 | 13 | 1 |
| 1 = Fair | 12 | 24 | 7 |
| 2 = Good | 37 | 24 | 2 |
| 3 = Very good | 23 | 13 | 8 |
| 4 = Excellent | 11 | 5 | 1 |
Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Very poor | 1 | 3 | 9 |
| 2 = Rather poor | 12 | 22 | 11 |
| 3 = Neither poor nor good | 33 | 31 | 9 |
| 4 = Rather good | 47 | 36 | 12 |
| 5 = Very good | 9 | 10 | 3 |
Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Very restless | 1 | 3 | 5 |
| 2 = Rather restless | 26 | 29 | 17 |
| 3 = Neither restless nor calm | 18 | 24 | 5 |
| 4 = Rather calm | 48 | 42 | 13 |
| 5 = Very calm | 9 | 4 | 4 |
Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Very difficult | 3 | 8 | 9 |
| 2 = Rather difficult | 29 | 33 | 6 |
| 3 = Neither difficult nor easy | 22 | 27 | 14 |
| 4 = Rather easy | 36 | 23 | 12 |
| 5 = Very easy | 12 | 11 | 3 |
Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Woke up much too early | 24 | 31 | 21 |
| 2 = Woke up somewhat too early | 45 | 52 | 11 |
| 3 = No | 33 | 19 | 12 |
Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Very difficult | 0 | 3 | 0 |
| 2 = Rather difficult | 1 | 0 | 2 |
| 3 = Neither difficult nor easy | 17 | 16 | 5 |
| 4 = Rather easy | 56 | 53 | 14 |
| 5 = Very easy | 28 | 30 | 23 |
Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = Not rested at all | 7 | 9 | 13 |
| 2 = Somewhat unrested | 53 | 55 | 17 |
| 3 = Completely rested | 42 | 38 | 14 |
Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 1 = No, definitely too little | 2 | 10 | 13 |
| 2 = No, much too little | 8 | 10 | 6 |
| 3 = No, somewhat too little | 18 | 27 | 8 |
| 4 = Yes, almost enough | 52 | 34 | 11 |
| 5 = Yes, definitely enough | 22 | 21 | 6 |
Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.
| Scores on a scale | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Subjective Sleep Questionnaire - Quality of Your Sleep Last Night | 6.5 ± 1.95 | 5.8 ± 2.11 | 4.9 ± 3.04 |
Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)
| Scores on a scale | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night | 6.6 ± 2.15 | 5.7 ± 2.20 | 4.6 ± 2.85 |
Subjects responded to Estimate of how long it took to fall asleep (minutes)
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Subjective Sleep Questionnaire - Time to Fall Asleep Last Night | 39.5 ± 36.63 | 40.2 ± 38.10 | 40.0 ± 42.66 |
Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed | 111.1 ± 121.86 | 144.8 ± 125.58 | 98.4 ± 89.71 |
Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain
| Scores on a scale | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Change From Baseline in Pain Intensity | 2.4 ± 0.48 | 2.4 ± 0.49 | 2.5 ± 0.50 |
The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 0 = No relief | 24 | 30 | 35 |
| 1 = A little relief | 5 | 3 | 4 |
| 2 = Some relief | 10 | 15 | 5 |
| 3 = A lot of relief | 47 | 37 | 8 |
| 4 = Complete relief | 21 | 21 | 2 |
If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded
| Minutes | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Time to Rescue Medication | NA (NA to NA) | NA (NA to NA) | 146.50 (118.00 to 314.00) |
If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded
| participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| ≤ 60 minutes | 0 | 1 | 0 |
| ≤ 120 minutes | 9 | 12 | 21 |
| ≤ 180 minutes | 14 | 13 | 29 |
| ≤ 240 minutes | 15 | 17 | 32 |
| ≤ 300 minutes | 16 | 23 | 33 |
| ≤ 360 minutes | 17 | 25 | 34 |
| ≤ 420 minutes | 21 | 26 | 35 |
| ≤ 480 minutes | 22 | 28 | 35 |
| ≤ 540 minutes | 24 | 30 | 35 |
| ≤ 600 minutes | 24 | 30 | 35 |
The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).
| Participants | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| 0 = Poor | 1 | 1 | 1 |
| 1 = Fair | 4 | 3 | 5 |
| 2 = Good | 22 | 25 | 3 |
| 3 = Very good | 40 | 38 | 9 |
| 4 = Excellent | 18 | 12 | 1 |
| mmHg | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2 | -1.3 ± 12.65 | -0.6 ± 13.51 | 2.2 ± 11.77 |
| mmHg | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2 | 0.7 ± 10.58 | -0.2 ± 8.42 | 2.1 ± 8.83 |
| Beats/min | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2 | 1.0 ± 10.57 | -0.1 ± 11.94 | 4.7 ± 12.65 |
| Breaths/min | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2 | -1.4 ± 3.12 | -1.2 ± 2.97 | -0.3 ± 2.70 |
Collected over Treatment emergent adverse events (TEAEs) were collected from the date of the first dose of study drug in the treatment period for 2 days, or for 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | — | 0/107 (0%) | 21/107 (19.6%) |
| Naproxen Sodium 440 mg (BAYH6689) | — | 0/106 (0%) | 14/106 (13.2%) |
| DPH 50 mg | — | 0/54 (0%) | 17/54 (31.5%) |
| Event | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 6/107 | 3/106 | 10/54 |
| DizzinessNervous system disorders | 9/107 | 9/106 | 2/54 |
| NauseaGastrointestinal disorders | 6/107 | 4/106 | 2/54 |
| Cold sweatSkin and subcutaneous tissue disorders | 3/107 | 0/106 | 1/54 |
| Vision blurredEye disorders | 1/107 | 0/106 | 1/54 |
| VomitingGastrointestinal disorders | 1/107 | 0/106 | 1/54 |
| Feeling jitteryGeneral disorders | 0/107 | 0/106 | 1/54 |
| Procedural complicationInjury, poisoning and procedural complications | 0/107 | 0/106 | 1/54 |
| Blood pressure increasedInvestigations | 0/107 | 0/106 | 1/54 |
| PollakiuriaRenal and urinary disorders | 0/107 | 0/106 | 1/54 |
| Age, Continuous(Years) | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg | Total |
|---|---|---|---|---|
| Mean | 21.4 ± 5.55 | 21.3 ± 5.27 | 20.8 ± 4.64 | 21.2 ± 5.25 |
| Sex: Female, Male(Participants) | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg | Total |
|---|---|---|---|---|
| Female | 72 | 64 | 37 | 173 |
| Male | 35 | 42 | 17 | 94 |
| Baseline Categorical Pain Rating Scale(Participants) | Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) | Naproxen Sodium 440 mg (BAYH6689) | DPH 50 mg | Total |
|---|---|---|---|---|
| No pain | 0 | 0 | 0 | 0 |
| Mild pain | 0 | 0 | 0 | 0 |
| Moderate pain | 69 | 63 | 28 | 160 |
| Severe pain | 38 | 43 | 26 | 107 |
The record gives a start of Dec 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 4 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen